Drug Profile
Dorgenmeltucel-L - Lumos Pharma
Alternative Names: HyperAcute Melanoma; Melanoma immunotherapy - Lumos Pharma; NLG-12036Latest Information Update: 27 Apr 2023
Price :
$50
*
At a glance
- Originator NewLink Genetics Corporation
- Developer Lumos Pharma; NewLink Genetics Corporation
- Class Cancer vaccines; Cell therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant melanoma
Most Recent Events
- 07 Aug 2015 Dorgenmeltucel-L is still in phase II trials for Malignant melanoma in the USA
- 25 Feb 2014 NewLink Genetics Corporation plans a phase IIb trial for Malignant melanoma in USA (NCT02054520)
- 01 Jun 2012 Final efficacy, immunogenicity and adverse events data from a phase II trial in Malignant melanoma presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO-2012)